Onego Bio Ltd: Precision Fermentation for European Food Security and Strategic Autonomy

Onego Bio Ltd is redefining how Europe can produce a staple protein—egg white—without a single chicken. This Finnish biotech spin-off has emerged from a national research lab with a mission that resonates far beyond the food industry. By using precision fermentation to create real ovalbumin (the key egg white protein) in yeast-like bioreactors, Onego Bio offers a glimpse into a more resilient and sustainable food supply.

Its innovative Bioalbumen powder delivers the full functionality of egg whites without the environmental or biosecurity risks of poultry farming. In an era when Europe’s strategic autonomy is scrutinized in domains from energy to semiconductors, an unlikely contender like egg protein is proving to be strategically significant. Onego Bio’s technology promises not only climate-friendly food production, but also a buffer against supply shocks – think avian flu outbreaks or trade disruptions – that can threaten food security.

By anchoring this cutting-edge biomanufacturing capability in the EU, the company is quietly reinforcing European resilience. The story of Onego Bio is about more than making meringues without chickens; it’s about European science turning a humble ingredient into a strategic asset, and doing so with an urgency and ambition that has attracted both venture capital and European innovation funding. It is a journey that speaks to Europe’s broader drive for technological sovereignty in critical sectors, even those not traditionally linked with defense.

Onego Bio Ltd is a deep-tech academic spin-off founded in Finland (2022) that produces animal-free egg white protein via precision fermentation. The company’s technology aligns with Europe’s Emerging Disruptive Technology (EDT) priorities in biotechnology, offering a sustainable protein source that can strengthen food security and supply chain resilience. Privately held by European and allied investors (including Finnish government funds and the European Innovation Council), Onego Bio has rapidly scaled its R&D from lab to pilot, reaching roughly TRL 6-7 with a patented fermentation platform.